October 16, 2012
$30.9M Series B Investment closed and Joel Martin appointed as President and CEO
September 07, 2011
Cebix to Chair Symposium on C-Peptide and the Pathophysiology of Diabetes at European Association for the Study of Diabetes Annual Meeting 2011
Assessment of C-peptide in Type 1 Diabetes on Neuropathy
ClinicalTrials.gov Identifier: NCT01681290
People who have type 1 diabetes lose beta-cell function and the ability to produce insulin and C-peptide. Currently available treatments focus on replacing insulin but not C-peptide. Published clinical studies suggest that C-peptide is an active hormone in its own right and may be useful in treating complications of type 1 diabetes, particularly loss of sensation (neuropathy). It is estimated that 60-70% of all people with diabetes will eventually develop peripheral neuropathy. Cebix Incorporated is evaluating a long-acting form of C-peptide (Ersatta™) in an ongoing phase 2 clinical trial (Act1ve) in the United States, Canada, and Sweden. The trial will track a measure of nerve function called nerve conduction velocity (NCV). NCV has been demonstrated as a quantifiable measure of nerve function that correlates with sensory deficits in the hands and feet, and is considered to be an early indicator of neuropathy.
In the Act1ve trial, participants will receive once-weekly injections of Ersatta (~60% of participants) or placebo (~40% of participants) for a year. If you qualify to participate, you will receive at no cost to you all study-related care, exams and medical testing from the study doctor, investigational drug, as well as compensation for time and travel.
In order to qualify for this trial you must meet the following criteria:
• Have type 1 diabetes for a minimum of 5 years;
• Be on a stable diabetic regimen (for at least 3 months);
• Be between 18-65 years old.
North American sites are located in California, Georgia, Idaho, Massachusetts, Michigan, Montana, Nebraska, Nevada, New York, and Texas, and the Canadian Provinces of Alberta, Ontario, and Quebec.
If you meet these criteria and are interested in participating or learning more about the Act1ve trial, please contact Lina Willis at 858-729-6501 or via email at firstname.lastname@example.org. Additional information regarding the Act1ve trial is also available on ClinicalTrials.gov by clicking on the following link: ClinicalTrials.gov Identifier: NCT01681290 .